STATE OF THE ART PAPER
Influence of standardization of human papillomavirus diagnosis in head and neck cancer treatment
1
Genetics and Molecular Biology Research Unit – UPGEM, Molecular Biology Department, São José do Rio Preto Medical School – FAMERP, São Paulo, Brazil
Submission date: 2021-12-02
Acceptance date: 2022-07-19
Publication date: 2022-09-01
Arch Med Sci Civil Dis 2022;7(1):1-9
KEYWORDS
TOPICS
ABSTRACT
The presence of human papillomavirus (HPV) in patients with head and neck squamous cell carcinoma (HNSCC) can guide medical management. The aim of this study was to highlight the importance of HPV diagnosis, verifying which diagnostic techniques are most used in identifying HPV and the differences between these techniques, in the research aimed at establishing a consensus on the gold standard method. We verify that HPV infection is associated with the development of HNSCC. The techniques most commonly used for diagnosis of HPV are immunohistochemistry (IHC), polymerase chain reaction (PCR), reverse transcription polymerase chain reaction (RT-PCR) and in situ hybridization (ISH). Our study concludes that detection of E6/E7 DNA by PCR is the most accepted method of diagnosis. The standardization of an accurate HPV diagnostic method can reduce morbidity and mortality in HNSCC, especially in emerging countries, where few screenings are performed, in addition to improving the social and economic impact of the disease.
REFERENCES (59)
1.
Beck TN, Golemis EA. Genomic insights into head and neck cancer. Cancers Head Neck 2016; 1: 1.
2.
Qiao XW, Jiang J, Pang X, et al. The evolving landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol 2020; 11: 1721.
3.
Castro TPPG, Filho IB. Prevalence of human papillomavirus (HPV) in oral cavity and oropharynx. Rev Bras.
5.
Li S, Lee YCA, Li Q, et al. Oral lesions, chronic diseases and the risk of head and neck cancer. Oral Oncol 2015; 51: 1082-7.
6.
Pan C, Issaeva N, Yarbrough WG. HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis. Cancers Head Neck 2018; 3: 12.
7.
Petito G, Dos Santos Carneiro MA, de Rabello Santos SH, et al. Human papillomavirus in oral cavity and oropharynx carcinomas in the central region of Brazil. Braz J Otorhinolaryngol 2017; 83: 38-44.
8.
Erira A, Motta LA, Chala A, et al. Genotipificación, niveles de expresión y estado físico del virus del papiloma humano en pacientes colombianos con cáncer de células escamosas en la cavidad oral. Biomédica 2016; 36 Suppl 2.
9.
Contreras W, Venegas B. Virus Papiloma Humano en Cáncer Oral y Orofaríngeo. Revisión de la Literatura. Int J Odontostomat 2015; 9: 427-35.
10.
Chang F, Syrjanen S, Kellokoski J, Syrjanene K. Human papillomavirus (HPV) infections and their associations with oral disease. J Oral Pathol Med 1991; 20: 305-17.
12.
Shewale JB, Gillison ML. Dynamic factors affecting HPV-attributable fraction for head and neck cancers. Curr Opin Virol 2019; 39: 33-40.
13.
Yang D, Shi Y, Tang Y, et al. Effect of HPV infection on the occurrence and development of laryngeal cancer: a review. J Cancer 2019; 10: 4455-62.
14.
Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 2004; 68: 362-72.
15.
Prati B, Marangoni B, Boccardo E. Human papillomavirus and genome instability: from productive infection to cancer. Clinics 2018; 73 (Suppl 1): e539s.
16.
Linge A, Schotz U, Lock S, et al. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiother Oncol 2018; 127: 27-35.
17.
Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503-6.
18.
Mulvany NJ, Allen DG, Wilson SM. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 2008; 40: 335-44.
19.
Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009; 10: 321-2.
20.
Boscolo-Rizzo P, del Mistro A, Bussu F, et al. New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital 2013; 33: 77-87.
21.
Ilardi G, Russo D, Varricchio S, et al. HPV virus transcriptional status assessment in a case of sinonasal carcinoma. Int J Mol Sci 2018; 19: 883.
22.
Miller ED, Dukagjin MB, Grecula JC. Sinonasal adenoid cystic carcinoma: treatment outcomes and association with human papillomavirus. Head Neck 2017; 39: 1405-11.
23.
Yang L, Wang H, Wang Y, et al. Prostate tumor overexpressed-1, in conjunction with human papillomavirus status, predicts outcome in early-stage human laryngeal squamous cell carcinoma. Oncotarget 2016; 7: 31878-91.
24.
Betiol J, Villa LL, Sichero L. Impact of HPV infection on the development of head and neck cancer. Braz J Med Biol Res 2013; 46: 217-26.
25.
Chaturvedi AK, Graubard BI, Broutian T, et al. NHANES 2009-2012 findings: association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res 2015; 75: 2468-77.
26.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636.
27.
Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009; 4: 8.
28.
Chocolatewala NM, Chaturvedi P. Role of human papilloma virus in the oral carcinogenesis: an Indian perspective. J Cancer Res Ther 2009; 5: 71-7.
29.
Delgado Ramos GM, Cotter TG, Flor Ramos L, et al. A pilot study on the identification of human papillomavirus genotypes in tongue cancer samples from a single institution in Ecuador. Braz J Med Biol Res 2018; 51: e7810.
30.
Husain N, Neyaz A. Human papillomavirus associated head and neck squamous cell carcinoma: controversies and new concepts. J Oral Biol Craniofac Res 2017; 7: 198-205.
31.
Wotman M, Oh EJ, Ahn S, et al. HPV status in patients with nasopharyngeal carcinoma in the United States: a SEER database study. Am J Otolaryngol 2019; 40: 705-10.
32.
Broglie MA, Jochum W, Michel A, et al. Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer. Oral Oncol 2017; 70: 43-50.
33.
Aggarwal C, Cohen RB, Morrow MP, et al. Immunotherapy targeting HPV16/18 generates potent immune responses in HPV-associated head and neck cancer. Clin Cancer Res 2019; 25: 110-24.
35.
Minami K, Kogashiwa Y, Ebihara Y, et al. Human papillomavirus and p16 protein expression as prognostic biomarkers in mobile tongue cancer. Acta Otolaryngol 2017; 137: 1121-6.
36.
Devaraja K, Aggarwal S, Verma SS, et al. Clinico-pathological peculiarities of human papilloma virus driven head and neck squamous cell carcinoma: a comprehensive update. Life Sci 2020; 245: 117383.
37.
Lefevre M, Rousseau A, Rayon T, et al. Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. Br J Cancer 2017; 116: 362-9.
38.
Boscolo-Rizzo P, Pawlita M, Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat Rev 2016; 42: 24-9.
39.
Simonato L, Tomo S, Garcia JF, et al. HPV detection in floor of mouth squamous cell carcinoma by PCR amplification. J Bras Patol Med Labor 2016; 52: 43-9.
40.
Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 2016; 91: 386-96.
41.
Descamps G, Karaca Y, Lechien JR, et al. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. J Cancer Res Clin Oncol 2016; 142: 2185-96.
42.
Granados-García M. Oropharyngeal cancer: an emergent disease? Salud pública de méxico, México 2016; 58: 285-90.
43.
Božinović K, Sabol I, Rakusic Z, et al. HPV-driven oropharyngeal squamous cell cancer in Croatia – demography and survival. PLoS One 2019; 14: e0211577.
44.
Schroeder L, Boscolo-Rizzo p, Dal Cin E, et al. Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: a retrospective multicentre study. Eur J Cancer 2017; 74: 73-81.
45.
Lewis JS, Beadle B, Bishop JA, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med 2018; 142: 559-97.
46.
Bussu F, Ragin C, Boscolo-Rizzo P, et al. HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice. Head Neck 2019; 41: 1104-11.
47.
Economopoulou P, de Bree R, Kotsantis I, Psyrri A. Diagnostic tumor markers in head and neck squamous cell carcinoma (HNSCC) in the clinical setting. Front Oncol 2019; 9: 827.
48.
Wai KC, Strohl MO, van Zante A, Ha PK. Molecular diagnostics in human papillomavirus-related head and neck squamous cell carcinoma. Cells 2020; 9; 500.
49.
Randén-Brady R, Carpen T, Jouhi L, et al. In situ hybridization for high-risk HPV E6/E7 mRNA is a superior method for detecting transcriptionally active HPV in oropharyngeal cancer. Hum Pathol 2019; 90: 97-105.
50.
Mena M, Taberna M, Tous S, et al. Double positivity for HPV-DNA/p16 ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients. Oral Oncol 2018; 78: 137-44.
51.
Bhosale PG, Pandey M, Desai RS, et al. Low prevalence of transcriptionally active human papilloma virus in Indian patients with HNSCC and leukoplakia. Oral Surg Oral Med Oral Pathol Oral Radiol 2016; 122: 609-18.e7.
52.
Yakin M, Seo B, Hussaini H, et al. Human papillomavirus and oral and oropharyngeal carcinoma: the essentials. Aust Dent J 2019; 64: 11-8.
53.
Augustin J, Mandavit M, Outh-Gauer S, et al. HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population. Mod Pathol 2018; 31: 1645-52.
54.
Channir HI, Kiss K, Rubek N, et al. Comparison of clinical, radiological and morphological features including the distribution of HPV E6/E7 oncogenes in resection specimens of oropharyngeal squamous cell carcinoma. Oral Oncol 2018; 78: 163-70.
55.
Sannigrahi MK, Sharma R, Singh V, et al. Role of host miRNA Hsa-miR-139-3p in HPV-16-induced carcinomas. Clin Cancer Res 2017; 23: 3884-95.
56.
Quijano Gutiérrez R. Cáncer orofaríngeo y vírus del papiloma humano encabeza y cuello: relaciones fisiopatológicas y epidemiológicas. Rev Costar Salud Pública 2018; 27 16-23.
57.
Blumberg J, Monjane L, Prasad M, et al. Investigation of the presence of HPV related oropharyngeal and oral tongue squamous cell carcinoma in Mozambique. Cancer Epidemiol 2015; 39: 1000-5.
58.
Hong A, Lee CS, Jones D, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head Neck 2016; 38: 743-50.
59.
Dong Z, Hu R, Du Y, et al. Immunodiagnosis and immunotherapeutics based on human papillomavirus for HPV-induced cancers. Front Immunol 2020; 11: 586796.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
